SEMAGLUTIDE

Semaglutide (Ozempic, Wegovy, Rybelsus) is Novo Nordisk’s GLP-1 RA (glucagon-like peptide-1 receptor agonist)—a modified 34-amino-acid peptide mimicking endogenous incretin hormones. FDA-approved 2017 (T2D) / 2021 (obesity), it delivers 15–20% weight loss, A1C reductions, and CV risk ↓26% (SUSTAIN-6). Weekly auto-injector transformed metabolic therapy.

Breakthrough: Brain-gut axis mastery—satiety + glucose control.

Development & Structure

GLP-1 (7-37) backbone +:

• Aib8: DPP-4 resistance.
• Lys26 C20 fatty diacid: Albumin binding → t1/2 1 week.
• Oral (Rybelsus): SNAC absorption enhancer.

Pharmacology: GLP-1R 94% activation; minimal GIPR cross-talk.

Mechanism: Multi-Target Metabolic Control

1. Pancreas: ↑Insulin, ↓glucagon (glucose-dependent).
2. Gut: Gastric emptying ↓60%.
3. Brain: Hypothalamus satiety (POMC/CART ↑).
4. Heart: Anti-atherosclerotic, inflammation ↓.
5. Liver: Steatosis -50%.

Landmark Clinical Evidence

STEP 1 (Obesity, NEJM 2021, n=1961)

SELECT (CVOT, 2023)

• 17,604 obese non-diabetics: MACE ↓20%, HF ↓ (5.4yr).

SUSTAIN-FORTE (T2D)

NASH: 59% resolution (ESSENCE Phase 3).

Optimized Dosing Protocols

SubQ (Ozempic/Wegovy):

Oral (Rybelsus): 3→7→14mg daily (fasted).

Transformative Benefits

1. Weight Loss: Class-leading; 1/3 lose >20%.
2. T2D Remission: 50%+ off insulin.
3. Cardiovascular: #1 for obese CV risk.
4. NASH: Biopsy-proven reversal.
5. QoL: Hunger ↓85%, energy normalization.

Side Effects & Management

Muscle Preservation: Protein 1.6g/kg + resistance (lean loss 30–40%).

Head-to-Head: Semaglutide Dominance

UK/EU Access Ecosystem

Compounding: Shortage workaround (purity varies).

Pipeline & Future

• Oral Semaglutide 50mg: Phase 3 (25% loss).
• Amycretin (GLP-1/amylin oral): Novo next-gen.
• OASIS-1 Kids: Pediatric obesity.

SELECT Subgroup: Even normal-weight CV benefit.

Conclusion: Semaglutide’s Legacy

From diabetes to obesity epidemic—semaglutide rewrote medicine. CagriSema 25%+ awaits.

Disclaimer: Prescription-only; comprehensive monitoring.